The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Open accessAbstract
The number needed to treat—the number of patients who must be treated to prevent one adverse outcome—is a widely used measure. 1 2 It is increasingly being calculated by pooling absolute risk differences in trials included in meta-analyses. 3 4 This option is available in statistical software and the Cochrane Database of Systematic Reviews . 5 6 In this paper, we examine pooled numbers needed to treat derived from trials and meta-analyses of interventions to prevent cardiovascular disease. We show that a pooled number needed to treat may be misleading because of variation in the event rates in trials, differences in the outcomes considered, effects of secular trends on disease risk, and differences in clinical setting. The number needed to treat should be derived by applying the relative risk reductions from treatment which have been estimated by trials or meta-analysis to relevant baseline risks for different types of patients. This provides a range of possible numbers needed to treat in different patient groups. ### Summary points Numbers needed to treat are often used to summarise treatment effects in a clinically relevant way They are derived from the baseline risk without treatment and the reduction in risk achieved with treatment Numbers needed to treat are sensitive to factors that change the baseline risk such as the outcome considered, patients' characteristics, secular trends in incidence and case fatality, and the clinical setting Pooled numbers needed to treat derived from meta-analyses can be seriously misleading because the baseline risk often varies appreciably between the trials Applying the pooled relative risk reductions calculated from meta-analyses or individual trials to the baseline risk relevant to specific patient group produces a useful number needed to treat The interventions selected for study were use of statins for lowering cholesterol concentrations in primary and secondary prevention of coronary heart disease.7 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Meta-analysis: Principles and procedures
Egger, M., Smith, G. D., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7121.1533 · Cited by 2,415
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
Meta-analysis. Beyond the grand mean?
Smith, G. D., Egger, M., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7122.1610 · Cited by 174
Cited by
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citationGraham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Antiplatelet agents for preventing pre-eclampsia and its complications
Duley, L., Henderson-Smart, D. J., Meher, S., & King, J. F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004659.pub2 · Cited by 1,016
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
(2001) · Europe PMC (PubMed Central) · Cited by 393
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Fodor, L. A., Coteț, C. D., Cuijpers, P., Szamoskozi, Ș., David, D., & Cristea, I. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28113-6 · Cited by 284
Simpson's paradox and calculation of number needed to treat from meta-analysis
Cates, C. J. (2002) · BMC Medical Research Methodology · doi:10.1186/1471-2288-2-1 · Cited by 251
Can meta-analysis help target interventions at individuals most likely to benefit?
Thompson, S. G., & Higgins, J. P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70200-2 · Cited by 174
Number needed to treat (NNT) in clinical literature: an appraisal
Mendes, D., Alves, C., & Batel-Marques, F. (2017) · BMC Medicine · doi:10.1186/s12916-017-0875-8 · Cited by 169
da Costa, B. R., Rutjes, A. W., Johnston, B. C., Reichenbach, S., Nüesch, E., Tonia, T., Gemperli, A., Guyatt, G. H., & Jüni, P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys124 · Cited by 145
Meta-analysis of rare and adverse event data
Sutton, A. J., Cooper, N. J., Lambert, P. C., Jones, D. R., Abrams, K. R., & Sweeting, M. J. (2002) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2.4.367 · Cited by 141
Measurement in clinical trials: A neglected issue for statisticians?
Senn, S., & Julious, S. (2009) · Statistics in Medicine · doi:10.1002/sim.3603 · Cited by 136
Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
Jenkins, D. J. A., Spence, J. D., Giovannucci, E. L., Kim, Y.-I., Josse, R. G., Vieth, R., Sahye-Pudaruth, S., Paquette, M., Patel, D., Blanco Mejia, S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.619 · Cited by 110
Number needed to treat (NNT): estimation of a measure of clinical benefit
Walter, S. D. (2001) · Statistics in Medicine · doi:10.1002/sim.1173 · Cited by 80
Systematic reviews experience major limitations in reporting absolute effects
Alonso-Coello, P., Carrasco-Labra, A., Brignardello-Petersen, R., Neumann, I., Akl, E. A., Vernooij, R. W. M., Johnston, B. C., Sun, X., Briel, M., Busse, J. W., et al. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.11.002 · Cited by 70
Self-citationRelative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy
Brown, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100074 · Cited by 11
“"When numbers needed to treat are presented for an intervention, the setting in which it occurred, the time period, the outcome, and the baseline risk of the patients for whom the number needed to treat is thought to be applicable should be described" [28].”
Absolute risk reduction may depend on the duration of the follow-up
Ferenci, T. (2017) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1102008 · Cited by 2
Metadata
- Authors
- Smeeth, L., Haines, A., & Ebrahim, S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1999-06-05
- Volume
- 318
- Issue
- 7197
- Pages
- 1548-1551
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2026077821
- Cited by
- 302
- References
- 10
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.